Thalidomide measurement in plasma and dried plasma spot by SPE combined with UHPLC-MS/MS for therapeutic drug monitoring.
Renata Soares NovellinoMarc Yves ChalomPaschoalina RomanoPersio de Almeida Rezende EbnerJulia Celestino SeraphimAna Carolina Silva do AmaralNilo Jose Coelho DuarteTatiana Do Nascimento PedrosaEmily Figueiredo Neves YukiNádia Emi AikawaSandra Gofinet PasotoClovis Artur Almeida da SilvaValdemir Melechco CarvalhoEloisa S BonfaLeonard de Vinci Kanda KupaPublished in: Bioanalysis (2022)
Aims: To validate an SPE-ultra-HPLC-MS/MS method for thalidomide (THD) measurement in dried plasma spot (DPS). Methods: Extraction included acetonitrile/water clean-up and online SPE. The LOD, LLOQ, linearity, precision, accuracy, recovery, matrix effect, process efficiency, carryover, stability, drug interference and dilution integrity were assessed. Results: The method was linear from 50 to 2000 ng/ml with a LOD of 20 ng/ml and LLOQ of 50 ng/ml. The coefficient of variation for precision was 0.4-7.9% for intra-assay and 1.3-8.9% for interassay, and accuracy was 81.4-97.1%. Adequate matrix effect (100.6-107.0%), recovery (88.7-105.0%) and process efficiency (91.3-109.3%) were registered. DPS was stable for 14 days at room temperature and 45°C ,and for 4 months at -80°C. The method was applied to quantify THD in both wet plasma and DPS from patients with cutaneous lupus receiving THD treatment. The difference between THD wet plasma and DPS concentration was <15%. Conclusion: The method is suitable to quantify THD in DPS.
Keyphrases
- ms ms
- room temperature
- liquid chromatography tandem mass spectrometry
- solid phase extraction
- magnetic resonance imaging
- social media
- high resolution
- healthcare
- rheumatoid arthritis
- computed tomography
- combination therapy
- liquid chromatography
- tandem mass spectrometry
- adverse drug
- drug induced
- replacement therapy
- high resolution mass spectrometry